TrialDiabetes, obesity & metabolism2017

Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.

Lawrence A Leiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.